Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Enterprise Value (2016 - 2025)

Bioadaptives' Enterprise Value history spans 8 years, with the latest figure at -$158445.0 for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 15.26% to -$158445.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$158445.0, a 15.26% decrease, with the full-year FY2025 number at -$158445.0, down 15.26% from a year prior.
  • Enterprise Value hit -$158445.0 in Q4 2025 for Bioadaptives, down from -$59273.0 in the prior quarter.
  • Over the last five years, Enterprise Value for BDPT hit a ceiling of -$235.0 in Q2 2024 and a floor of -$210582.0 in Q2 2025.
  • Historically, Enterprise Value has averaged -$66054.8 across 5 years, with a median of -$50235.5 in 2022.
  • Biggest five-year swings in Enterprise Value: soared 99.41% in 2024 and later tumbled 89509.36% in 2025.
  • Tracing BDPT's Enterprise Value over 5 years: stood at -$83126.0 in 2021, then surged by 69.39% to -$25447.0 in 2022, then crashed by 138.83% to -$60776.0 in 2023, then tumbled by 126.19% to -$137470.0 in 2024, then fell by 15.26% to -$158445.0 in 2025.
  • Business Quant data shows Enterprise Value for BDPT at -$158445.0 in Q4 2025, -$59273.0 in Q3 2025, and -$210582.0 in Q2 2025.